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Abstract
Background: Creatine synthesis takes place predominately in the kidney and liver via a two-step
process involving AGAT (L-arginine:glycine amidinotransferase) and GAMT (guanidinoacetate
methyltransferase). Creatine is taken into cells via the creatine transporter (CrT), where it plays
an essential role in energy homeostasis, particularly for tissues with high and fluctuating energy
demands. Very little is known of the fetal requirement for creatine and how this may change with
advancing pregnancy and into the early neonatal period. Using the spiny mouse as a model of human
perinatal development, the purpose of the present study was to comprehensively examine the
development of the creatine synthesis and transport systems.
Results: The estimated amount of total creatine in the placenta and brain significantly increased in
the second half of pregnancy, coinciding with a significant increase in expression of CrT mRNA. In
the fetal brain, mRNA expression of AGAT increased steadily across the second half of pregnancy,
although GAMT mRNA expression was relatively low until 34 days gestation (term is 38–39 days).
In the fetal kidney and liver, AGAT and GAMT mRNA and protein expression were also relatively
low until 34–37 days gestation. Between mid-gestation and term, neither AGAT or GAMT mRNA
or protein could be detected in the placenta.
Conclusion: Our results suggest that in the spiny mouse, a species where, like the human,
considerable organogenesis occurs before birth, there appears to be a limited capacity for
endogenous creatine synthesis until approximately 0.9 of pregnancy. This implies that a maternal
source of creatine, transferred across the placenta, may be essential until the creatine synthesis and
transport system matures in preparation for birth. If these results also apply to the human,
premature birth may increase the risk of creatine deficiency.
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The creatine/phosphocreatine (PCr) system plays an
essential role in cellular energy homeostasis, serving as a
spatial and temporal energy buffer in cells with high and
fluctuating energy demands (for detailed reviews see [1-
4]). In adult humans, about half of the creatine require-
ment is obtained from the diet, with the remainder syn-
thesized endogenously in a two-step sequence involving
AGAT (L-arginine:glycine amidinotransferase) and GAMT
(guanidinoacetate methyltransferase). The first step
involving AGAT occurs mostly in the kidney where
arginine and glycine form guanidinoacetate, which later
undergoes methylation to form creatine, occurring mostly
in the liver via the actions of GAMT.
From the liver, creatine is carried in the blood to creatine-
requiring tissues, where it is transported into cells against
a large concentration gradient by a creatine-specific, high
affinity, sodium- and chloride-dependent creatine trans-
porter protein (CrT) located at the plasma membrane
[2,5]. Once inside the cell, creatine kinase regulates the
phosphorylation of creatine.
The recently discovered congenital defects in humans
affecting creatine synthesis (AGAT or GAMT deficiency),
or creatine uptake (CrT deficiency), are characterized by a
severe depletion of cerebral creatine/PCr [6]. In early
infancy, these patients often show neurodevelopmental
delay, mental retardation, inability to speak, epileptic sei-
zures, autism, movement disorders, and are prone to
developmental myopathies [7-9]. No amount of creatine
supplementation can improve clinical outcomes in CrT
deficient patients [7,10]. In AGAT-deficient patients, long-
term high dose creatine supplementation offers a clear
therapeutic benefit, whereas in GAMT-deficient patients,
in order to reduce accumulation of toxic guanidinoace-
tate, creatine supplementation has to be accompanied by
arginine restriction and ornithin supplementation to be
effective [11]. Two recent case studies suggest pre-sympto-
matic creatine supplementation may completely prevent
the neurological sequelae when treatment is initiated
within 1–4 months of birth, although long term progress
is yet to be monitored [12,13].
The reported success of this early intervention creatine
supplementation suggests that the fetus only becomes
depleted of cerebral creatine after birth. It may be that the
mother and/or placental unit sustain the fetal creatine
requirement for all of pregnancy [12,13]. The human pla-
centa is known to express CrT RNA [14], and the capacity
for maternal-to-fetal transfer of creatine occurs from at
least 13 weeks of gestation onwards [15]. In the pregnant
rat, such creatine transfer occurs from at least 14 days ges-
tation [15], and the placenta and fetus show an increasing
capacity for creatine accumulation (relative to maternal
plasma) with advancing gestation [16]. These results sug-
gest that the placental creatine content probably increases
with gestation, possibly in conjunction with an increase in
the expression or activity of the CrT, however this has not
been shown in any species.
Very little is known of the fetal requirement for creatine
and how this may change with advancing pregnancy and
into the early neonatal period, particularly for tissues
known to have a high creatine requirement in the adult
(e.g. brain, heart, skeletal muscle) [2]. Braissant and col-
leagues have shown that in the embryonic rat CrT mRNA
is expressed in almost all tissues, including the brain, from
as early as embryonic day (E) 12.5 [17]. The brain shows
a marked increase in expression of CrT at E15.5 (term is
approximately 21 days). These authors did not measure
the content of creatine in the developing fetus, so it
remains unknown whether and how the pattern of CrT
expression actually relates to brain creatine levels.
In the adult mouse brain, CrT expression at the blood
brain barrier has been shown to be a major pathway for
supplying creatine to the brain [18]. However, neurons,
astrocytes and oligodendrocytes in the adult rat brain
have been shown to express the creatine synthesizing
enzymes, implying that at least some of the brain require-
ment for creatine is met by de novo synthesis [17,19]. In
the developing rat brain, AGAT mRNA can be detected in
isolated cells of the central nervous system (CNS) from
E12.5 onwards, although GAMT mRNA expression is still
only barely detectable at E18.5 [17]. It would appear that
at the time of birth the rat pup has only a very limited
capacity for creatine synthesis within the CNS. It is neces-
sary to understand how these expression patterns change
in the postnatal period, as the newborn rat pup does not
reach a comparable stage of development to the newborn
human infant until at least postnatal day 7 [20,21].
In preparation for birth it is probable that, as for AGAT
and GAMT activities in the adult, the fetal kidney and liver
must develop an independent capacity for creatine syn-
thesis. In the developing rat, GAMT mRNA expression in
the liver shows a steady increase in expression between
E12.5–18.5, whereas AGAT mRNA in the kidney is not
detectable until E18.5 [17]. These results suggest the altri-
cial rat pup attains the capacity for creatine synthesis only
shortly before birth.
Previous studies in rodents have provided insight into the
temporal development of the fetal creatine synthesis and
transport system [17,22,23]. However, these findings
have not been related to the creatine content of fetal tis-
sues and the role of the placenta has not been considered.
Due to the relative immaturity of the newborn rat, the
changes leading up to birth do not appropriately reflect
the changes that are likely to occur in the human during
the transition from late gestation to early postnatal life.Page 2 of 12
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BMC Developmental Biology 2009, 9:39 http://www.biomedcentral.com/1471-213X/9/39The spiny mouse (Acomys cahirinus) is a precocial species
that can be considered an appropriate animal model for
perinatal development in the human. Unlike conven-
tional rats and mice, the spiny mouse has a long gestation
(38–40 days), small litter size (1–5, usually 3), and is
developmentally more advanced at birth; the body is cov-
ered with fur, eyes and ears are functional, they show
active olfaction and are capable of thermoregulation and
coordinated locomotion [24]. The developmental profiles
of the lung [25], liver [26], small intestine and pancreatic
enzymes [27], and the completion of nephrogenesis in
the kidney before term [28], indicate that, as in the
human, organogenesis is largely complete by the end of
gestation.
Using the spiny mouse as a model of human perinatal
development, the purpose of the present study was to
comprehensively examine the development of the creat-
ine synthesis and transport systems. We measured the cre-
atine content of fetal and placental tissues, and sought to
determine if the fetus had the capacity to meet its creatine
requirement independently of a maternal-placental
source.
Methods
Animals
All experiments were approved in advance by Monash
University School of Biomedical Sciences Animal Ethics
Committee, and conducted in accordance with the Aus-
tralian Code of Practice for the Care and Use of Animals
for Scientific Purposes. The spiny mice used in this study
were obtained from our own laboratory colony and
housed, bred and time-mated as previously described
[29].
Tissue preparation
Placental and fetal tissues were collected at gestational
days 20, 25, 30, 34 and 37, and neonatal tissues on post-
natal days 2 and 10, from at least 4 different litters for each
age (litter size range 2–4). Placentas and fetal and neona-
tal brain, heart, liver and kidneys were dissected, weighed
and snap frozen in liquid nitrogen and stored at -80°C.
Heart samples were collected only from gestational day 25
and kidney samples from day 30 due to the limited mass
of tissue.
Tissue creatine
The concentration of creatine and PCr were measured on
gestational days 20, 30, 34, 37 and postnatal day 10, as
previously described [30]. Briefly, tissues from 4 fetuses/
neonates of different litters were weighed (wet mass),
freeze dried for 24–48 h, powdered and re-weighed (dry
mass). Powdered samples (1–4 mg dry mass) were
extracted on ice using 0.5 M perchloric acid and 1 mM eth-
ylenediaminetetraacetic acid, and neutralized with 2.1 M
potassium hydrogen carbonate. Samples were assayed for
creatine and PCr using enzymatic analysis with fluoro-
metric detection [31]. Due to insufficient tissue mass after
freeze drying, measures were not taken for the heart, liver
or kidney on the earliest gestational time point at day 20.
The estimated amount of total creatine (TCr; creatine +
PCr) was determined as: sample tissue TCr concentration
× (sample tissue dry mass/sample tissue wet mass) × total
tissue wet mass.
Real-time PCR
Real-time polymerase chain reaction (qPCR) was used to
measure mRNA expression of CrT (in placenta, brain and
heart), AGAT (in placenta, brain and kidney), and GAMT
(in placenta, brain and liver) on gestational days 20, 25,
30, 34, 37, and postnatal days 2 and 10, from 4 animals
(of different litters) at each age.
Total RNA was extracted and DNase treated using the
commercially available RNeasy Kits (Qiagen, Australia)
for all samples except heart, which were extracted using
PerfectPure RNA Fibrous Tissue Kit (5 Prime, USA). Sam-
ple RNA (0.5–1.0 mg) was reversed transcribed to form
cDNA using AMV reverse transcriptase and Random Prim-
ers according to the manufacturer's instructions
(Promega, USA), and diluted 1:2 with nuclease-free water.
CrT, AGAT, GAMT and 18S primers (see Table 1) were
designed based on homologous regions across human,
mouse and rat nucleotide sequences (Ensembl Genome
Browser) using web based software Primer3Plus [32] and
NetPrimer (PREMIER Biosoft International). Optimum
Table 1: Sequence of forward and reverse primers for genes of interest and housekeeping genes
Gene Forward Primer Sequence (5'-3') Reverse Primer Sequence (5'-3')
18S ACACGGACAGGATTGACAGA CAAATCGCTCCACCAACTAA
CrT TCCTGGCACTCATCAACAG ATGAAGCCCTCCACACCTAC
AGAT TCACGCTTCTTTGAGTACCG TCAGTCGTCACGAACTTTCC
GAMT TGGCACACTCACCAGTTCA AAGGCATAGTAGCGGCAGTC
b-actin GACAGGATGCAGAAGGAGATTACT TGATCCACATCTGCTGGAAGGT
Cyc A CTGATGGCGAGCCCTTG TCTGCTGTCTTTGGAACTTTGTC
CrT, creatine transporter; AGAT (L-arginine:glycine amidinotransferase); GAMT, (guanidinoacetate methyltransferase); Cyc A, cyclophilin A.Page 3 of 12
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mined using a primer annealing temperature gradient
(range 55.2–65.1°C). All samples were measured in trip-
licate, and each plate included a calibrator sample and a
reaction containing no template (negative control).
For all samples except heart, qPCR was performed using
an Eppendorf Mastercycler® ep realplex S with RealMaster-
Mix SYBR ROX (5 Prime, USA). Each 20 ml reaction con-
tained 1–3 ml template (1 ml for CrT; 3 ml for AGAT and
GAMT) and 0.5 mM of each forward and reverse primer. A
3-step PCR was used to amplify mRNA with an initial tem-
plate denaturing of 95°C for 2 min, followed by 40 cycles
of; 95°C for 15 sec, 64.4, 55.4 or 59.6°C for 15 sec (CrT,
AGAT and GAMT, respectively), and 68°C for 20 sec. A
fourth step of 80.5°C for 20 sec was included when ampli-
fying AGAT and GAMT mRNA to remove primer-dimer
artefact that occurred with low expression of the genes of
interest. Heart samples were assayed for CrT using a Strat-
agene MX3000p thermal cycler system with SYBR Green
PCR Mastermix (Applied Biosystems, USA). Each 20 ml
reaction contained 2 ml template and 0.2 mM of each for-
ward and reverse primer. A 3-step PCR was used to
amplify mRNA; initial template denaturing of 95°C for 10
min, and 40 cycles of; 95°C for 30 sec, 60.0°C for 60 sec,
and 72°C for 30 sec. Fluorescence readings were meas-
ured during the last step of cycling.
A melt curve of fluorescence versus temperature was per-
formed after each qPCR to ensure a single product had
been amplified per primer set. The DNA product of each
gene of interest, housekeeping gene, and negative controls
were run on a 2 percent agarose gel to confirm single
product at the expected size (Figure 1).
Data were analyzed and differential expression deter-
mined using the comparative DDCT (cycle of threshold flu-
orescence) method. Briefly, relative expression in each
sample were calculated by subtracting the mean CT value
for 18S from the mean CT value of the gene of interest; DCT
value. The mean DCT value of the calibrator sample was
then subtracted from each individual sample to give
DDCT. This number was inserted into the formula 2-DDCT
and divided by the mean 2-DDCTvalue of the 37 day gesta-
tion group, therefore expressed relative to the mean of the
37 day gestation group for the gene of interest within each
organ. The expression stability of the housekeeping gene
18S between gestational day 20 and postnatal day 10 was
verified for all organs of interest against b-actin and cyclo-
philin A using geNorm (internal control gene-stability
measure for 18S <1.2 for all organs) [33].
Immunoblotting
Western blotting technique was used to measure AGAT
protein expression in placenta, brain, and kidney, as well
as GAMT protein expression in placenta, brain, and liver
homogenates from 4 animals of different litters at select
ages between 20 days gestation and postnatal day 10. The
proteins were detected with affinity purified rabbit mono-
clonal (GAMT) and polyclonal antibodies (AGAT) made
through injection of the following antigenic peptides:
GAMT N-terminal aa 125–145; and AGAT N-terminal aa
62–77 and 410–423. Specific immunoglobulins against
AGAT and GAMT were obtained by peptide affinity chro-
matography. The antibodies detected a positive band at
the predicted molecular mass (AGAT, 46 kDa; GAMT, 31
kDa; see Figure 2). No signal was detected in the negative
control sample (adult skeletal muscle, [1]).
There has been considerable difficulty in quantifying CrT
protein. This is largely due to glycosylation and the diffi-
culties associated with hydrophobic proteins in gels [34],
but also because of non-specific immunoreactivity of sev-
eral anti-CrT antibodies [35]. These antibodies have been
shown to cross-react with non-CrT proteins, in particular
E2 components of mitochondrial dehydrogenases [35].
Specificity of primers for genes of interest and housekeeping genesFigure 1
Specificity of primers for genes of interest and house-
keeping genes. A single DNA product was detected at the 
expected size for each set of primers; 18S = 86 bp, CrT = 
250 bp, AGAT = 182 bp, GAMT = 245 bp, b-actin = 142 bp, 
cyclophilin A = 67 bp. bp, base pairs; bAct, b-actin; Cyc, 
cyclophilin A.
Specificity of anti-AGAT and anti-GAMT antibodies in spiny mouse tissueFig re 2
Specificity of anti-AGAT and anti-GAMT antibodies 
in spiny mouse tissue. Antibodies were reactive for a pos-
itive band at the expected size, with no positive reaction 
observed in the negative control sample (skeletal muscle). 
MM, molecular mass marker; SkM, skeletal muscle.Page 4 of 12
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BMC Developmental Biology 2009, 9:39 http://www.biomedcentral.com/1471-213X/9/39We generated a rabbit monoclonal antibody against the
CrT N-terminal aa 14–27. In the spiny mouse, the anti-
body labelled more than one band within the predicted
molecular mass range (50–75 kDa, data not shown). As
yet we have been unable to verify if one or more of these
bands is indeed recognizing the genuine CrT. For these
reasons, only mRNA data could be obtained for the CrT.
Protein was extracted using Cell Lysis Buffer (Cell Signal-
ling Technology, USA) and 1 mM serine protease inhibi-
tor phenylmethylsulphonyl fluoride (PMSF). Protein
concentrations were determined using the Lowry method
with a bovine serum albumin (BSA) standard curve. Sam-
ples were prepared with Laemmli sample buffer (0.225 M
Tris-HCl pH 6.8, 50% glycerol, 5% SDS, 0.05%
bromophenol blue, 0.25 M DTT) and heated at 95°C for
5 min, denaturing the tertiary structure. Prepared samples
(10 mg) and 2 ml broad range molecular mass marker were
separated using 15% SDS-PAGE gel, and wet electro-trans-
ferred (Mini Trans-blot, BioRad Laboratories, Australia) to
nitrocellulose blotting membrane. Transfer to membranes
was verified with reversible Ponceau S, and gels stained
with Coomassie Blue. Membranes were blocked for 120
min in 5% BSA in 0.1% Tween-20 TBS (20 mM tris, 500
mM NaCl, pH 7.4; TBST), and incubated in primary anti-
body with 5% BSA in TBST overnight at 4°C (anti-AGAT,
1:1000; anti-GAMT, 1:2000). Following incubation,
membranes were washed in TBST, incubated with HRP-
conjugated goat-anti-rabbit secondary antibody (1:5000,
Santa Cruz) and StrepTactin-HRP conjugate (1:10,000)
with 5% BSA in TBST at room temperature for 60 min,
and given a final wash in TBS. All incubations were per-
formed with gentle agitation. Reactive protein were
detected with chemiluminescence (Cell Signalling Tech-
nology, Australia) and exposed to X-ray film (Kodak, Aus-
tralia). Each blot contained a positive control sample, and
samples from 2 animals of each age group. Western blot
data were analyzed using ImageJ 1.40 g, with values
expressed relative to the positive control sample.
Reagents
Unless otherwise specified, all reagents were obtained
from BioRad Laboratories (Australia).
Statistical analysis
All data are presented as mean ± SE, and were analyzed
using a one-way analysis of variance with Tukey HSD post
hoc. Significance was set at p < .05. Statistical comparisons
were carried out using the computer based program SPSS.
Results
Organ growth and creatine
Figure 3A–E shows the mass and estimated amount of tis-
sue TCr in the placenta from mid-gestation until birth, as
well as in brain, heart, liver and kidney from mid-gesta-
tion to postnatal day 10. The estimated amount of TCr in
the placenta and brain showed a steady and significant
increase between 20–37 days gestation (p < .05, Figure
3A–B). In the brain, the TCr content continued to increase
in the postnatal period. Although the tissue mass
increased with age as expected for all organs, the esti-
mated amount of tissue TCr did not change in the fetal
heart, liver and kidney between 30–37 days gestation, but
it had increased significantly by postnatal day 10 (p < .05,
Figure 3C–E).
Enzymes of creatine synthesis in the kidney and liver
The developmental expression of the two key enzymes
involved in creatine synthesis, AGAT and GAMT, were
measured in the kidney and liver, respectively, at the
mRNA and protein level from mid-gestation until the sec-
ond postnatal week (Figure 4A–D). Expression of AGAT
mRNA in the kidney remained relatively low between 30
and 34 days of gestation, with a significant 33-fold
increase in expression by 37 days of gestation (p < .05, Fig-
ure 4A). A further increase had occurred by postnatal day
2 (p < .05), with no further change by postnatal day 10.
The expression of AGAT protein showed a similar profile;
protein levels significantly increased between gestational
days 30, 37 and postnatal day 10 (p < .05, Figure 4B).
There was relatively low expression of hepatic GAMT
mRNA between gestational days 20–30, with a significant
50-fold increase in expression by day 37 of gestation (p <
.05, Figure 4C). Expression was lower after birth, with the
postnatal mRNA levels being similar to that at 34 days of
gestation. The expression of GAMT protein increased sig-
nificantly between gestational days 20 and 34–37, similar
to the mRNA profile, however a further significant
increase in GAMT protein occurred by postnatal day 10 (p
< .05, Figure 4D).
Enzymes of creatine synthesis in the brain
AGAT mRNA expression showed a gradual increase
between gestational days 20, 25, 30, 34 and 37, although
only reached significance between days 20 and 37 (p <
.05, Figure 5A). A further 2-fold increase in AGAT mRNA
expression occurred by postnatal day 2 (p < .05), and
remained unchanged at postnatal day 10. Expression of
GAMT mRNA in the fetal brain was relatively low between
20–30 days gestation, with a significant 10-fold increase
by 34 days gestation (p < .05, Figure 5B). Levels remained
unchanged by 37 days gestation and into the postnatal
period. Although mRNA for both AGAT and GAMT were
detected, the corresponding proteins could not be
detected by Western blot analysis (data not shown).
Enzymes of creatine synthesis in the placenta
AGAT and GAMT could not be detected in any placenta
samples between 20 and 37 days of gestation at the mRNA
or protein level (data not shown).Page 5 of 12
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The estimated amount of tissue TCr (n) and wet mass () of placental, fetal and neonatal tissues during developmentFigure 3
The estimated amount of tissue TCr (n) and wet mass () of placental, fetal and neonatal tissues during devel-
opment. A, Placenta; B, Brain; C, Heart; D, Liver; E, Kidney. Data points not sharing the same symbol indicate amount of tis-
sue TCr is significantly different to all others (p < .05). Mean ± SE. TCr, total creatine; GA, gestational days; PN, postnatal days.
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The expression of CrT mRNA was determined from mid-
gestation until postnatal day 10 (Figure 6). In the placenta
and brain, CrT mRNA expression was detected early on in
pregnancy and showed a significant 2-fold increase in
expression from gestational day 20 to 37 (p < .05, Figure
6A–B). In the brain, a further increase occurred postna-
tally, with CrT mRNA increasing a further 2.3-fold
between late gestation (day 37) and postnatal day 10. In
the heart, CrT mRNA increased approximately 2-fold
between gestational days 30–34, although this did not
reach significance (P = 0.35; Figure 6C).
Discussion
The provision of creatine to the tissues of a developing
embryo is likely to be important for normal fetal develop-
ment, particularly for energy homeostasis in the brain and
heart. Despite this, very little is known about when creat-
ine synthesis and its transporter system develops during
embryonic, fetal and neonatal life. In this study we used a
species that, like the human, has a relatively long gesta-
tion during which considerable fetal development and
maturation occurs. We determined that the amount of
TCr in the spiny mouse placenta and fetal brain increased
progressively across the second half of gestation. How-
Expression of the creatine synthesizing enzymes AGAT and GAMT in the kidney and liver during fetal and neonatal develop-mentFigure 4
Expression of the creatine synthesizing enzymes AGAT and GAMT in the kidney and liver during fetal and 
neonatal development. A, Kidney AGAT mRNA expression; B, Kidney AGAT protein expression; C, Liver GAMT mRNA 
expression; D, Liver GAMT protein expression. All mRNA data are normalized to 18S and shown relative to 37 days gestation. 
Data points not sharing the same symbol indicate expression is significantly different to all others (p < .05). Mean ± SE. GA, 
gestational days; PN, postnatal days.
A.  Kidney AGAT mRNA C. Liver  GAMT mRNA 
B.  Kidney AGAT protein D. Liver  GAMT protein Page 7 of 12
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enzymes AGAT and GAMT in the fetal kidney, liver and
brain was low until very late in gestation (days 34–37),
and expression of these enzymes in the placenta was not
detected at all. These results suggest that in precocial spe-
cies the developing fetus is almost completely reliant on a
maternal source of creatine until as late as 0.9 of preg-
nancy.
The fetal brain showed a steady and significant increase in
the estimated amount of TCr from mid-gestation until
term, and increased further in the postnatal period. The
high amount of creatine found in this organ is not surpris-
ing, as the adult brain is known to have a high basal crea-
tine concentration, presumably to cope with its large and
fluctuating cellular energy requirements [3,4].
In the adult rat brain, there is a limited capacity for creat-
ine to cross the blood brain barrier. The widespread
expression of creatine synthesizing enzymes has lead to
the suggestion that the creatine requirements of the brain
can be met, at least in part, independently of extra-CNS
sources (i.e. that synthesized via the kidney and liver)
[19]. In the spiny mouse, although AGAT and GAMT
mRNA could be measured in whole brain extracts, protein
expression could not be detected with western blot analy-
sis. On the basis of this result, it could be argued that the
fetal and neonatal brain does not have the capacity to syn-
thesize creatine in significant amounts on a whole organ
level. A more likely explanation is that, as for the rat,
AGAT and GAMT protein expression in the fetal spiny
mouse brain is region and cell-specific [17]. Immunoblot
with whole brain homogenate is most likely too insensi-
tive to detect such protein expression.
The temporal difference in the appearance of AGAT and
GAMT mRNA in the fetal spiny mouse brain is an interest-
ing phenomenon. A similar result was found for the
embryonic rat, where AGAT could be detected from E12.5,
yet GAMT was barely detectable even shortly before birth
at E18.5 [17]. These results suggest that the fetal brain
relies on extra-CNS or maternal sources of creatine for the
whole of pregnancy, and/or the creatine precursor guanid-
inoacetate is transferred from the CNS to GAMT-express-
ing cells where it can be converted to creatine. Although
our results have not been confirmed at the protein level,
the expression patterns of AGAT and GAMT mRNA sug-
gest that the fetal spiny mouse brain does not attain an
appreciable capacity for significant creatine synthesis until
shortly before birth, at 34–37 days gestation (0.9 of preg-
nancy).
We showed that CrT mRNA expression in the spiny mouse
brain increased approximately 2-fold between mid-preg-
nancy and term; we were unable to measure CrT protein
for lack of an appropriately specific antibody (as detailed
in Methods). This prenatal increase is in agreement with
that described in the embryonic rat [17], and consistent
Expression of the creatine synthesizing enzymes AGAT and GAMT in the brain during fetal and neonatal developmentFigure 5
Expression of the creatine synthesizing enzymes AGAT and GAMT in the brain during fetal and neonatal 
development. A, Brain AGAT mRNA expression; B. Brain GAMT mRNA expression. All mRNA data are normalized to 18S 
and shown relative to 37 days gestation. AGAT and GAMT protein could not be detected with western blot, possibly due to 
low level expression in whole brain homogenates. Data points not sharing the same symbol indicate expression is significantly 
different to all others (p < .05). Mean ± SE. GA, gestational days; PN, postnatal days.
A.  Brain AGAT mRNA  B.  Brain GAMT mRNA Page 8 of 12
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Creatine transporter mRNA expression in the developing spiny mouse placenta, brain and heartFigure 6
Creatine transporter mRNA expression in the developing spiny mouse placenta, brain and heart. A, Placental 
CrT mRNA expression; B, Brain CrT mRNA expression; C, Heart CrT mRNA expression. All mRNA data are normalized to 
18S and shown relative to 37 days gestation. Data points not sharing the same symbol indicate expression is significantly differ-
ent to all others (p < .05). Mean ± SE. GA, gestational days; PN, postnatal days.
A.  Placenta CrT mRNA 
B.  Brain CrT mRNA
C.  Hear t CrT mRNA
BMC Developmental Biology 2009, 9:39 http://www.biomedcentral.com/1471-213X/9/39with its early expression in zebra fish [36]. Further
increases in CrT expression in the spiny mouse brain were
observed at 2 and 10 days after birth. In the neonatal rat
brain, the concentration of creatine and creatine kinase
has been reported to increase significantly between post-
natal weeks 1 and 3, with levels essentially remaining
unchanged after that [37,38]. It is likely that the pre- and
postnatal developmental increase in brain CrT expression
in the spiny mouse coincides with the increasing demand
for creatine in the maturing CNS, which cannot be met
entirely by creatine synthesis within the CNS.
AGAT and GAMT expression in the fetal kidney and liver
were also relatively low until the very late stages of preg-
nancy; a 30 to 50-fold increase in mRNA expression was
seen at 34–37 days of gestation (term is ~39 days). We
expected that in preparation for birth these key organs
would develop a capacity for creatine synthesis in the lat-
ter half of pregnancy, but these results suggest a limited
capacity for endogenous creatine synthesis exists until
very late (~0.9) in pregnancy. AGAT and GAMT expres-
sion levels in the kidney and liver remained unchanged
between gestational day 37 and postnatal day 10. It would
appear that shortly before birth, the spiny mouse attains
the capacity to meet the postnatal requirement for endog-
enous creatine synthesis. It would be interesting to know
how the uptake of creatine from breast milk contributes to
the neonatal requirement for creatine in the spiny mouse.
Similar to the brain, the amount of TCr measured in the
placenta of the spiny mouse increased significantly with
advancing pregnancy. Being metabolically very active, it is
likely that the placenta itself has a requirement for creat-
ine – creatine kinase expression, which is tightly coupled
with cellular energy requirements, peaks in term human
placenta [39]. However, as for the human placenta [4], it
appears that this organ itself does not synthesize creatine,
as we were unable to detect either AGAT or GAMT mRNA
or protein in the placenta of the spiny mouse from mid-
gestation to term. The increase in placental TCr may reflect
an increase in a temporary pool of 'stored creatine' availa-
ble for transfer to the fetus, which is consistent with our
observation that there was an increase of CrT mRNA in the
placenta from at least mid-gestation. At the present time
we do not know whether this occurs in maternal or fetal
tissue in the placenta. The increase coincides with the
development of the labyrinth region of the placenta,
which is primarily fetal tissue and associated with the
rapid expansion of the fetal vascular compartment [40].
An increase in placental CrT may allow for more efficient
transfer of creatine into the fetal circulation with increas-
ing gestation – thus meeting the fetus' growing demand
for creatine, particularly that of the fetal brain.
To our knowledge, the transcriptional pathways control-
ling the regulation of the CrT, AGAT and GAMT genes
have not been identified. In the fetal spiny mouse, circu-
lating thyroid hormone increases steadily between 30
days gestation and term [41]. Analysis of the CrT pro-
moter reveals approximately six nuclear respiratory factor
1 (NRF1) consensus sequences, for which thyroid hor-
mone is a known activator of [42]. It is plausible that the
CrT gene is regulated, at least in part, via a thyroid hor-
mone/NRF1 transcriptional program, however this is yet
to be established.
Although the fetal heart, liver and kidney undergo consid-
erable growth from mid-gestation until term in the fetal
spiny mouse, the estimated amount of TCr did not
increase until after birth. Although heart muscle does not
synthesize creatine, as with skeletal muscle it has a large
requirement for creatine and therefore a considerable
capacity for uptake and storage [1]. Our finding that heart
TCr did not increase until the postnatal period is in agree-
ment with previous studies in the rat, where creatine lev-
els, as well as creatine kinase levels, increased 5-fold in the
3 weeks after birth [37,38]. As cardiovascular function is
of fundamental importance for growth from very early in
pregnancy [43], it is not altogether surprising that cardiac
creatine levels are relatively high and stable throughout
gestation. The quantity of creatine found in the heart from
gestational day 30 is obviously sufficient to sustain car-
diac function until term. However, at birth the heart
undergoes rapid growth and re-modelling associated with
transformation of the circulation with the onset of pulmo-
nary ventilation and closure of the major vascular shunts,
the ductus arteriosus and foramen ovale. Thus, between
gestational day 37 and postnatal day 10 the mass of the
heart increased almost 3-fold, TCr content increased 2-
fold, and CrT mRNA expression increased 2-fold between
mid-gestation and postnatal day 10 (although this did not
reach significance). It is possible that creatine uptake into
the heart is facilitated by an increase in CrT activity rather
than CrT protein expression, and further increases in
transporter expression may occur later than postnatal day
10. In support of this, is the fact that CrT activity can be
regulated by phosphorylation via protein kinases [44,45].
Unlike the brain and skeletal muscle, the kidney and liver
have less requirement for creatine [46]. The observed
rapid increase in TCr in these organs in the postnatal
period is likely to reflect their functional maturation. The
kidney plays a key role in the re-absorption of creatine
from urine, the capacity for which has been shown to
increase after birth in both the human and rat [47]. Like-
wise, the methylation of guanidinoacetate to creatine, a
process occurring predominantly in the liver, also appears
to increase after birth.
Conclusion
These results suggest that, for a species where considerable
maturation of the fetus occurs before birth, there appearsPage 10 of 12
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until approximately 0.9 of pregnancy. This implies that a
maternal source of creatine, transferred to the fetus via the
placental unit, may be essential until the creatine/PCr syn-
thesis and transport system matures in preparation for
birth. If these results also apply to the human, it may be
that infants born prematurely would be at risk of becom-
ing creatine deficient, unless sufficient creatine can be
absorbed by the immature gut from the limited amounts
of creatine present in breast milk [12]. Organs with the
highest energy requirements, such as the brain and heart,
would be at greatest risk at this time. Also, fetal growth-
retardation arising from chronic placental insufficiency
may also result in high risk for creatine deficiency, as our
results suggest that the placenta has an essential role in the
transfer of creatine from mother to fetus. We have previ-
ously shown that creatine supplementation of the mater-
nal diet is of benefit to the fetus when exposed to severe
hypoxia at birth [30]. Creatine supplementation may also
benefit the growth-retarded fetus, especially since many of
these are also born preterm.
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